High-dose vitamins can be dangerous! no protection against gastrointestinal cancer or cardiovascular disease
Becker, W.
Lakartidningen 102(10): 728
2005
ISSN/ISBN: 0023-7205 PMID: 15839162 Document Number: 593635
Document emailed within 1 workday
Related Documents
Rosenblatt, K.A.; Thomas, D.B.; Noonan, E.A. 1992: High-dose and low-dose combined oral contraceptives: protection against epithelial ovarian cancer and the length of the protective effect. the WHO Collaborative Study of Neoplasia and Steroid Contraceptives European Journal of Cancer 28a (11): 1872-1876Rosenblatt, K.A.; Thomas, D.B.; Noonan, E.A. 1992: High-dose and low-dose combined oral contraceptives: protection against epithelial ovarian cancer and the length of the protective effect. the WHO Collaborative Study of Neoplasia and Steroid Contraceptives European Journal of Cancer 28a (11): 1872-1876
Antimi, M. 1998: High-dose chemotherapy of breast cancer with hematopoietic protection; current status and prospectives La Clinica Terapeutica 149(921): 7-9
Jacobsen, D.W. 1998: Homocysteine and vitamins in cardiovascular disease Clinical Chemistry 44(8 Pt 2): 1833-1843
Quinlivan, E.P.; Gregory, J.F. 2006: Homocysteine, B vitamins, and cardiovascular disease New England Journal of Medicine 355(2): 206; Author Reply 209-211
2010: Vitamins and minerals: not for cancer or cardiovascular prevention Prescrire International 19(108): 182
Gordon, J.E.; Schooff, M. 2002: Can high-dose supplementation with vitamins C and E, beta carotene, and zinc slow the progression of macular degeneration? Journal of Family Practice 51(2): 105
El-Sabban, F.M. 2009: Current stand on supplementation with antioxidant vitamins in cardiovascular disease Saudi Medical Journal 30(7): 969-970
Lissoni, P.; Brivio, F.; Brivio, O.; Fumagalli, L.; Gramazio, F.; Rossi, M.; Emanuelli, G.; Alderi, G.; Lavorato, F. 1995: Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients Journal of Biological Regulators and Homeostatic Agents 9(1): 31-33
Lala, A.; Berger, J.S. 2011: Percutaneous coronary intervention for acute coronary syndromes: no difference in 30-day efficacy or safety of high- and low-dose aspirin; double-dose clopidogrel reduces 30-day risk of cardiovascular death, myocardial infarction or stroke compared with standard dose but increases risk of major bleeding Evidence-Based Medicine 16(3): 80-81
Yu, Z.H.; Cong, L.K.; Li, W.C.; Tan, B.B. 1988: Improving myocardial protection with high-dose insulin Chinese Medical Journal 101(8): 571-578
Yang, C; Southwell, B G. 2004: Dangerous disease, dangerous women: health, anxiety and advertising in Shanghai from 1928 to 1937 Critical Public Health 14(2): 149-156
Fennelly, D.W.; Aghajanian, C.; Shapiro, F.; O'Flaherty, C.; O'Connor, K.; Curtin, J.P.; Crown, J.P.; Hoskins, W.J.; Spriggs, D.R. 1997: Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer Seminars in Oncology 24(1 Suppl 2: S2
Razis, E.D.; Samonis, G.; Cook, P.; Beer, M.; Mittelman, A.; Lake, D.E.; Feldman, E.J.; Puccio, C.; Ahmed, T. 1994: TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer Journal of Medicine 25(3-4): 241-250
Nakano, K.; Yamamoto, M.; Iwamoto, H.; Hiramoto, T. 2003: Daily low-dose cisplatin plus concurrent high-dose thoracic radiotherapy in elderly patients with locally advanced unresectable non-small-cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(9): 1283-1287
Bearman, S.I.; Shpall, E.J.; Jones, R.B.; Cagnoni, P.J.; Ross, M. 1996: High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer Seminars in Oncology 23(1 Suppl 2: 60-67
Eckert, S.; Tschöpe, D. 2005: Cardiovascular protection in diabetic patients with heart disease in the doctor's office MMW Fortschritte der Medizin 147(43): 43-46
Pellizzer, A.M.; Krum, H. 1996: ACE inhibitors in cardiovascular disease. which patient? which drug? which dose? Australian Family Physician 25(7): 1067-1069; 1072-3; 1076-1077
Zhu, W.-x.; Chen, B.-s. 2005: The study progression of recombinant apolipoprotein A-IMilano in cardiovascular protection and therapy of coronary heart disease Zhonghua Xin Xue Guan Bing Za Zhi 33(7): 673-675
Capizzi, R.L.; Powell, B.L. 1987: Sequential high-dose ara-C and asparaginase versus high-dose ara-C alone in the treatment of patients with relapsed and refractory acute leukemias Seminars in Oncology 14(2 Suppl 1: 40-50